Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Holmgren U"'
Publikováno v:
International Journal of COPD, Vol Volume 17, Pp 2987-3000 (2022)
Enrico de Nigris,1 Catrin Treharne,2 Nick Brighton,2 Ulf Holmgren,3 Andrew Walker,4 John Haughney5 1Formerly of Global Product and Portfolio Strategy, AstraZeneca, Cambridge, UK; 2Formerly of Health Economic Modelling, Regulatory and Access, Parexel
Externí odkaz:
https://doaj.org/article/8748e70acdde40f985bd7266bc9ee2ce
Publikováno v:
International Journal of COPD, Vol Volume 16, Pp 1303-1314 (2021)
John R Hurst,1 Mohd Kashif Siddiqui,2 Barinder Singh,3 Precil Varghese,4 Ulf Holmgren,5 Enrico de Nigris6 1UCL Respiratory, University College London, London, UK; 2HEOR and RWE Analytics, Regulatory Access, Parexel International Ltd, Mohali, India; 3
Externí odkaz:
https://doaj.org/article/e2a5387d6dc149c9a01c30842f5f5f91
Publikováno v:
International Journal of COPD, Vol Volume 15, Pp 3261-3271 (2020)
Jennifer K Quint,1 Alessandra Venerus,2 Caroline O’Leary,2 Melissa Myland,2 Ulf Holmgren,3 Precil Varghese,4 Claudia Cabrera3,5 1Imperial College London, London, UK; 2IQVIA, London, UK; 3Real World Science and Digital, BioPharmaceuticals Medical, A
Externí odkaz:
https://doaj.org/article/fae1f05e75be4b759df96748b82f1443
Publikováno v:
International Journal of COPD, Vol Volume 13, Pp 927-936 (2018)
Bo Ding,1 Mark Small,2 Gina Scheffel,3 Ulf Holmgren3 1Medical Evidence and Observational Research, AstraZeneca Gothenburg, Mölndal, Sweden; 2Real World Research (Respiratory), Adelphi Real World, Bollington, UK; 3Global Payer Evidence and Pricing, A
Externí odkaz:
https://doaj.org/article/a644779243864e6e8bcf05cfdd6c38a0
Publikováno v:
International Journal of COPD, Vol Volume 12, Pp 1527-1537 (2017)
Bo Ding,1 Mark Small,2 Ulf Holmgren3 1Medical Evidence and Observational Research, AstraZeneca Gothenburg, Mölndal, Sweden; 2Real World Research (Respiratory), Adelphi Real World, Bollington, UK; 3Global Payer Evidence and Pricing, AstraZeneca Gothe
Externí odkaz:
https://doaj.org/article/3c05fc137bcc434f95786a8ea22f0fb1
Publikováno v:
International Journal of COPD, Vol Volume 12, Pp 529-539 (2017)
Bo Ding,1 Marco DiBonaventura,2 Niklas Karlsson,1 Gina Bergström,1 Ulf Holmgren1 1AstraZeneca Gothenburg, Mölndal, Sweden; 2Kantar Health, New York, NY, USA Introduction: Past research has suggested significant relationships between symptoms and he
Externí odkaz:
https://doaj.org/article/44bed450e2e7492fae3af0d2bd6ac5c1
Publikováno v:
International Journal of COPD, Vol Volume 12, Pp 589-599 (2017)
Bo Ding,1 Mark Small,2 Gina Bergström,1 Ulf Holmgren1 1Global Medical Affairs, AstraZeneca, Gothenburg, Sweden; 2Adelphi Real World, Bollington, UK Background: Sleep disturbance has been termed the forgotten dimension of chronic obstructive pulmonar
Externí odkaz:
https://doaj.org/article/3c2322bdeeea4d9db8042f830e083e31
Publikováno v:
International Journal of COPD, Vol Volume 12, Pp 677-689 (2017)
Bo Ding,1 Mark Small,2 Gina Bergström,3 Ulf Holmgren3 1Medical Evidence and Observational Research, AstraZeneca Gothenburg, Mölndal, Sweden; 2Real World Research (Respiratory), Adelphi Real World, Bollington, UK; 3Global Payer Evidence and Pricing,
Externí odkaz:
https://doaj.org/article/176891e5d4424fd1ace433332b469dce
Publikováno v:
In Value in Health December 2022 25(12) Supplement:S174-S174
Publikováno v:
In Value in Health January 2022 25(1) Supplement:S72-S73